Dinesh Khanna, MD, MSc

University of Michigan
Ann Arbor, MI, United States

Dinesh Khanna, MD, MSc, is the Frederick G.L. Huetwell Professor of Medicine and Director, University of Michigan Scleroderma Program. He is currently funded by the National Institutes of Heath with grants from NIAMS and NIAID (as part of Clinical Autoimmunity Center of Excellence). Dr Khanna has published over 400 peer-reviewed articles and book chapters. Dr Khanna is the Coordinating PI for ongoing and recently completed NIH and industry-funded trials of abatacept, brentuximab, pirfenidone, riociguat, tofacitinib, and tocilizumab in scleroderma. His current research is focused on validating outcome measures, trial design, and understanding the mechanism of action(s) of novel targets in the context of scleroderma clinical trials. He led the development of American College of Rheumatology Combined Response Index in Systemic Sclerosis (ACR CRISS) and Revised CRISS. Dr Khanna is recipient of the Henry Kunkel Young Investigator Award from the American College of Rheumatology.

Disclosure information not submitted.

Presentation(s):

• 0520: Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the Scleroderma Lung Study III

  Saturday, November 12, 2022
  3:30 PM – 3:40 PM Eastern Time

• 1521: Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial)

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time

• 247: Holding Court in Pulmonary Hypertension: Aggressive Management Strategies in Rheumatology Practice

  Monday, November 14, 2022
  7:30 PM – 9:00 PM Eastern Time